Patients demonstrating the CYP2C19*1/*17 genotype suffered mainly from skin (rash, erythema), nervous system (headache, vertigo), and gastrointestinal disorders (nausea, gastritis). This evidence concerns the gene CYP2C19 and digestive system disorder.